Omixon’s Developers Attended the SMRTLeiden Meeting 2017

23/05/2017

After last year’s success the second SMRTLeiden Meeting was held between May 2nd and 4th, at Leiden University Medical Center, Leiden, Netherlands. The conference included two events: the SMRT Scientific Symposium and the second European SMRT Informatics Developers Meeting. The two-day long Scientific Symposium featured presentations from key experts...

HLA Explore – New Genotyping Software for HLA by NGS

28/04/2017

Omixon announce the public release of HLA Explore 1.4. HLA Explore is HLA genotyping software for genetics/genomics researchers for the analysis and interpretation of any NGS data. It is high-performance, high-throughput and high-resolution multi-sample software for genotyping analysis, interpretation and reporting. The software – featured to analyse data from any...

Omixon Welcomes Nina Lauterbach to Our Field Application Scientist Team in Europe

27/04/2017

Please join us welcoming Dr. Nina Lauterbach to our Field Application Scientist Team! Nina received her Bachelor and Masters degree in Health Sciences at Maastricht University, the Netherlands. Following her Masters she completed her PhD at the department of Transplantation Immunology at the Maastricht University Medical Center, where she...

Organ Preservation – Science Versus Organ Shortage

25/04/2017

This month we are going to take a look at organ preservation, examining the current trends and establishing its importance in transplantation medicine. Why is organ preservation important? According to United Network of Organ Sharing (UNOS) – an excellent source of information when it comes to transplantation – there...

Omixon Welcomes Afshan Ali as Sales Manager, EMEA

12/04/2017

We are happy to announce that Afshan Ali has joined the team at Omixon’s global headquarters as a Sales Manager for the EMEA (Europe, Middle East and Africa). Afshan is a highly dynamic and successful Business Development Manager with extensive experience in working with Pharma, Diagnostics and Biotechnology companies...